Takeda Pharmaceutical (TAK) Inventory (2017 - 2026)

Takeda Pharmaceutical's Inventory history runs 10 years deep, the most recent figure standing at $8.9 billion for Q1 2026.

• On a quarterly basis, Inventory rose 11.61% year-over-year to $8.9 billion in Q1 2026; TTM through Mar 2026 was $8.9 billion, a 11.61% increase from a year earlier, with the FY2026 full-year figure at $9.3 billion, up 16.1% from the prior year.
• Inventory retreated to $8.9 billion in Q1 2026 per TAK's latest filing, from $9.1 billion in the prior quarter.
• Across five years, Inventory topped out at $9.1 billion in Q4 2025 and bottomed at $6.6 billion in Q4 2022.
• The 5-year median for Inventory is $8.0 billion (2023), against an average of $8.0 billion.
• Across the five-year window, Inventory declined 8.04% in 2022 and climbed 20.56% in 2023, its largest moves.
• Year by year, Inventory stood at $6.6 billion in 2022, then increased by 20.56% to $7.9 billion in 2023, then gained by 3.61% to $8.2 billion in 2024, then rose by 11.53% to $9.1 billion in 2025, then decreased by 2.6% to $8.9 billion in 2026.
• Per Business Quant, the three latest TAK Inventory figures stand at $8.9 billion (Q1 2026), $9.1 billion (Q4 2025), and $8.8 billion (Q3 2025).